CD103
Antigens, CD
/ genetics
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ antagonists & inhibitors
CD8 Antigens
/ genetics
CD8-Positive T-Lymphocytes
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cytotoxicity, Immunologic
/ drug effects
Gene Expression Regulation
Humans
Ikaros Transcription Factor
/ genetics
Immunologic Memory
Immunotherapy
/ methods
Integrin alpha Chains
/ genetics
Interleukin-17
/ genetics
Lung Neoplasms
/ drug therapy
Lymphocyte Activation
/ drug effects
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
/ drug effects
Phosphorylation
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
STAT3 Transcription Factor
/ genetics
Signal Transduction
Survival Analysis
Tumor Microenvironment
/ drug effects
Aiolos, AhR, and T-bet transcription factors
CD103 integrin
CD8 TRM cells
CTL
ICB response biomarkers
TCR repertoire
Tc17
anti-PD-1 immunotherapy
lung cancer
tumor-infiltrating lymphocytes
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 10 2020
20 10 2020
Historique:
received:
22
08
2019
revised:
24
07
2020
accepted:
24
09
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Accumulation of CD103
Identifiants
pubmed: 33205076
doi: 10.1016/j.xcrm.2020.100127
pii: S2666-3791(20)30169-5
pmc: PMC7659589
doi:
Substances chimiques
Antigens, CD
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
CD8 Antigens
0
IKZF3 protein, human
0
Integrin alpha Chains
0
Interleukin-17
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
alpha E integrins
0
Ikaros Transcription Factor
148971-36-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100127Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
B.B.’s sponsored research at Gustave Roussy Cancer Center consists of the following: Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals.
Références
J Immunol. 2005 Oct 1;175(7):4355-62
pubmed: 16177076
J Exp Med. 2018 Apr 2;215(4):1153-1168
pubmed: 29449309
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
J Exp Med. 2007 Mar 19;204(3):559-70
pubmed: 17325197
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Clin Cancer Res. 2017 May 15;23(10):2491-2505
pubmed: 27827318
J Immunol. 2006 Feb 1;176(3):1439-46
pubmed: 16424171
J Clin Invest. 2011 Jun;121(6):2254-63
pubmed: 21537083
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
J Exp Med. 2018 Oct 1;215(10):2520-2535
pubmed: 30154266
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Nature. 2019 Jul;571(7764):270-274
pubmed: 31207604
Nat Immunol. 2012 Jul 01;13(8):770-7
pubmed: 22751139
Immunity. 2004 Feb;20(2):167-79
pubmed: 14975239
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Proc Natl Acad Sci U S A. 2005 May 3;102(18):6437-42
pubmed: 15851656
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Nat Methods. 2017 Jul;14(7):687-690
pubmed: 28581496
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Immunity. 2017 Feb 21;46(2):287-300
pubmed: 28214226
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Science. 2016 Apr 22;352(6284):459-63
pubmed: 27102484
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Nature. 1994 Nov 10;372(6502):190-3
pubmed: 7969453
Int Immunol. 2011 Dec;23(12):751-9
pubmed: 22039016
Nat Commun. 2017 May 24;8:15221
pubmed: 28537262
Nat Immunol. 2013 Dec;14(12):1285-93
pubmed: 24162775
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
J Exp Med. 2019 Sep 2;216(9):2128-2149
pubmed: 31227543
J Exp Med. 2005 May 16;201(10):1647-57
pubmed: 15897278
Cancer Res. 2013 Jan 15;73(2):617-28
pubmed: 23188505
J Immunol. 2015 Mar 1;194(5):2059-63
pubmed: 25624457
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Nat Immunol. 2016 Dec;17(12):1467-1478
pubmed: 27776108
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Eur J Immunol. 2019 Jun;49(6):853-872
pubmed: 30891737
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
Cancer Res. 2016 Apr 1;76(7):1757-69
pubmed: 26921343
J Immunol. 2011 Jan 15;186(2):775-83
pubmed: 21160050
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Immunity. 2011 May 27;34(5):741-54
pubmed: 21600798
Sci Immunol. 2017 Mar;2(9):
pubmed: 28707003
J Urol. 2015 Aug;194(2):556-62
pubmed: 25752441
Nature. 2017 Dec 14;552(7684):253-257
pubmed: 29211713
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16741-6
pubmed: 21930933
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045
pubmed: 29599411
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
J Exp Med. 2019 Jul 1;216(7):1682-1699
pubmed: 31142588
Gynecol Oncol. 2010 Sep;118(3):228-36
pubmed: 20541243
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7037-42
pubmed: 22509047
Cancer Res. 2009 Aug 1;69(15):6249-55
pubmed: 19638592